p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines

Japanese Journal of Cancer Research

Volumn 87, Issue 7, 1996, Pages 735-742

  Hirota, Yasuhide ^a   Horiuchi, Tadashi ^a   Akahane, Kouichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cell cycle; Cell growth; Oligonucleotide; p53 antisense

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; MUTANT PROTEIN; PROTEIN P53; RNA;

ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COLON TUMOR; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA SYNTHESIS; TUMOR CELL LINE; TUMOR GROWTH;

EID: 0029764492     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb00286.x     Document Type: Article

References (38)

1. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. p53 Mutations in human cancers. Science, 253, 49-53 (1991).
2. Levine, A. J., Momand, J. and Finlay, C. A. The p53 tumour suppressor gene. Nature, 351, 453-456 (1991).
3. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell, 71, 587-593 (1992).
4. Lane, D. P. p53, guardian of the genome. Nature, 358, 15-16 (1992).
5. 1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
6. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
7. Xlong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704 (1993).
8. Bargonetti, J., Freidman, P. N., Kern, S. E., Vogelstein, B. and Prives, C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 65, 1083-1091 (1991).
9. Bargonetti, J., Manfredi, J., Chen, X., Marshak, D. and Prives, C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev., 7, 2565-2574 (1993).
10. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C. and Levine, A. J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6, 1143-1152 (1992).
11. Finlay, C. A., Hinds, P. W. and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57, 1083-1093 (1989).
12. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C. and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4, 42-46 (1993).
13. Shaulsky, G., Goldfinger, N. and Rotter, V. Alterations in tumour development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res., 51, 5232-5237 (1991).
14. Wolf, D., Admon, S., Oren, M. and Rotter, V. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis expression aberrant p53 mRNA species. Mol. Cell. Biol., 4, 552-558 (1984).
15. Chen, P.-L., Chen, Y., Bookstein, R. and Lee, W.-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1580 (1990).
16. Peacock, J. W. and Benchimol, S. Mutation of the endogenous p53 gene in cells transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism. EMBO J., 13, 1084-1092 (1994).
17. Bayever, E., Iversen, P., Smith, L., Spinolo, J. and Zon, G. Guest editorial: systemic human antisense therapy begins. Antisense Res. Dev., 2, 109-110 (1992).
18. Bayever, E., Haines, K., Iversen, P. L., Ruddon, R. W., Pirruccello, S. J., Mountjoy, C. P., Arneson, M. A. and Smith, L. J. Selective cytotoxicity to human leukemic myeloblasts produced by oligonucleotide phosphothioates complementary to p53 nucleotide sequences. Leuk. Lymphoma, 12, 223-231 (1994).
19. Shaulian, E., Zauberman, A., Ginsberg, D. and Oren, M. Identification of a minimal transforming domain of p53 : negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol., 12, 5581-5592 (1992).
20. Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V. and Lane, D. P p53 Mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87, 7555-7559 (1990).
21. Crooke, R. M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-cancer Drug Design, 6, 609-646 (1991).
22. Barker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915 (1990).
23. Hara, E., Tsurui, H., Shinozaki, A., Nakada, S. and Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun., 179, 528-534 (1991).
24. Deppert, W., Buschhausen-Danker, G., Patschinsky, T. and Steinmeyer, K. Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene, 5, 1701-1706 (1990).
25. Mercer, W. E., Nelson, D., Deleo, A. B., Old, L. J. and Baserga, R. Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc. Natl. Acad. Sci. USA, 79, 6309-6312 (1982).
26. Mercer, W. E., Avignolo, C. and Baserga, R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol. Cell. Biol., 4, 276-281 (1984).
27. Shohat, O., Greenberg, M., Reisman, D., Oren, M. and Rotter, V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene, 1, 277-283 (1987).
28. Donehower, L. A., Harvey, M., Slagle, B., McArthur, M., Montgomery, C. A. J., Butel, J. S. and Brafley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221 (1992).
29. Dutta, A., Ruppert, J. M., Aster, J. C. and Winchester, E. Inhibition of DNA replication factor RPA by p53. Nature, 365, 79-82 (1993).
30. Kanda, T., Segawa, K., Ohuchi, N., Mori, S. and Ito, Y. Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site. Mol. Cell. Biol., 14, 2651-2663 (1994).
31. Li, R. and Botchan, M. R. The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell, 73, 1207-1221 (1993).
32. Lin, D., Shields, M. T., Ullrich, S. J., Appella, E. and Mercer, W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA, 89, 9210-9214 (1992).
33. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appela, E. and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA, 87, 6166-6170 (1990).
34. Mercer, W. E., Shields, M. T., Lin, D., Appella, E. and Ullrich, S. J. Growth suppression induced by wild-type p 53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA, 88, 1958-1962 (1991).
35. Donehower, L. A. and Bradley, A. The tumor suppressor p53. Biochem. Biophys. Acta, 1155, 181-205 (1993).
36. Hupp, T. R., Meek, D. W., Midgley, C. A. and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71, 875-886 (1992).
37. Milner, J. A. conformational hypothesis for the suppressor and promoter functions of p53 in cell growth and in cancer. Proc. R. Soc. Lond. B, 245, 139-145 (1991).
38. Ullrich, S. J., Anderson, C. W., Mercer, W. E. and Appella, E. The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem., 267, 15259-15262 (1992).